DVLA
Darya-Varia Laboratoria Tbk
Financial snapshot+
Company information+
Major shareholders+
Management+
- dr. Ian Martin Wibawa Kloer
- Yustina Endang Setyowati
- Celso Paz Lim
- Dennis Tee Co
- Alexander S. Panlilio
- Jose Luis H. Narvaez
- Sonny Kalona
- Clinton Andrew Campos Hess
- Eric Albert Lim Gotuaco
- Mariano John Lim Tan, Jr.
- Marlia Hayati Goestam
- Sancoyo Antarikso
DVLA closed at 1.590 , -3.64% YTD and -6.47% over the trailing year. Over 52 weeks it has traded between 1.370 and 1.730. Current price sits in the 61th percentile of its 52-week range.
What you pay for, and what you get back.
How Darya-Varia Laboratoria Tbk compares to 0 peers in Farmasi & Riset Kesehatan.
- Kontan Market· 13 Apr 2026
PT Darya‑Varia Laboratoria Tbk (DVLA) posted a modest‑defensive 2025‑year‑end performance, with net profit rising about 5% year‑on‑year to Rp163.95 billion driven mainly by a 10.6% jump in gross margin despite only a 2.9% increase in cost of goods sold. Kiwoom Securities flagged rising liabilities (up 22.2% to Rp870.44 billion) and short‑term liquidity pressure, warning that any rebound in raw‑material prices could erode margins and keep earnings growth moderate. The analyst kept a “wait‑and‑see” stance on DVLA shares, noting that the stock’s price remains volatile while the broader IDX Composite (IHSG) stays buoyant but is also shadowed by external geopolitical risks.
— neutral
| Metric | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Revenue | 594.8B | 603.6B |
| Gross Profit | 301.4B | 326.8B |
| Operating Income | 68.9B | -4.2B |
| Net Income | 55.3B | -383.3M |
| EBITDA | 83.2B | 13.4B |
| Total Assets | 2.5T | 2.4T |
| Total Equity | 1.5T | 1.5T |
| Total Debt | 163.3M | 206.9M |
| Operating Cash Flow | 144.0B | 9.3B |
| Free Cash Flow | 124.5B | -23.2B |